Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 19/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 19/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 19/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657377 | 0.78 | CASP1 (0.38) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL7197657 | 0.76 | GABRG2 (0.54) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL2653715 | 0.73 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1 | |
| SCHEMBL6761392 | 0.70 | GABRG2 (0.40) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL2658798 | 0.70 | GABRA1 (0.44) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL6764518 | 0.69 | GABRG2 (0.43) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL2657958 | 0.69 | GABRG2 (0.35) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL341150 | 0.68 | GABRG2 (0.79) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL7001291 | 0.67 | GABRG2 (0.45) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL2652119 | 0.66 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730676-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS | MERCK SHARP & DOHME LTD. | 2004-05-04 | — | — | US | claimed |
| US-20030013716-A1 | Pyrazino-pyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-01-16 | — | — | US | claimed |
| US-6730676-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS | MERCK SHARP & DOHME LTD. | 2004-05-04 | — | — | US | disclosed |
| US-20030013716-A1 | Pyrazino-pyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013716-A1 | Pyrazino-pyridazine derivatives as ligands for gaba receptors | GABRA5, GABRA3, GABRA2 | GABRG2 18/4885GABRB3 7/4885GABRA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.